Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease

Clinical Neuropharmacology

Volumn 19, Issue 3, 1996, Pages 234-245

  Rascol, O ^a   Lees, A J ^b   Senard, J M ^a   Pirtosek, Z ^b   Montastruc, J L ^a   Fuell, D ^c  

^a INSERM   (France)

^b MIDDLESEX HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Levodopa; Motor fluctuations; Parkinson's disease; Ropinirole

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSKINESIA; FAINTNESS; FEMALE; FLUSHING; HUMAN; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029968682     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619030-00005     Document Type: Article

References (24)

1. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-93.
2. Vidailhet MJ, Bonnet AM, Balal S, Dubois B, Marle C, Agid Y. Ropinirole without levodopa in Parkinson's disease. Lancet 1990;336:316-7.
3. Kapoor R, Pirtosek Z, Frankel JP, et al. Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468. Lancet 1989;1(8652):1445-6.
4. Kleedorfer B, Stern GM, Lees AJ, Bottomlet JM, Sree Haran N. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:938.
5. Gibb W, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
6. Hoehn MY, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
7. Fahn S, Elton R, and the members of the UPDRS Development Commitee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-63.
8. Montastruc JL, Rascol O, Senard JM. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 1991;14:432-7.
9. Scholz E, Bacher M, Dichans J. Twenty-four-hour tremor recording in the evaluation of the treatment of Parkinson's disease. J Neurol 1988;235:475-84.
10. Van Hilten JJ, Kabel JF, Middlekoop HA, Kramer CG, Kerkhof GA, Roos RA. Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring. Acta Neurol Scand 1993;87:71-177.
11. Van Hilten JJ, Hoogland G, Van der Velde EA, Van Dijk JG, Kerkhof GA, Roos RA. Quantitative assessment of parkinsonian patients by continuous wrist activity monitoring. Clin Neuropharmacol 1993;16:36-45.
12. Stern GM, Lees AJ, Sandler M. Recent observations on the clinical pharmacology of (-) deprenyl. J Neural Transm 1978;43:245-51.
13. Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 1980;43:1016-21.
14. Broderson P, Philibert A, Gulliksen G, Stigard A. The effect of L-deprenyl on on-off phenomena in Parkinson's disease. Acta Neurol Scand 1985;71:494-7.
15. Lees AJ, Kohout LJ, Shaw KM, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:291-5.
16. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
17. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;ii:404-6.
18. Cedarbaum JM, Breck L, Kutt H, McDowell FH. Controlled-release levodopa/carbidopa. Neurology 1987;37:233-41.
19. Goetz CG, Olanow CW, Koller W, et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 1989;320:337-41.
20. Lindvall O, Rehncrona S, Brundin P, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989;46:615-31.
21. 2-dopaminergic agonist ropinirole on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers. Arzneimittelforshung 1990;40:1-7.
22. 2-receptor agonist. Br J Pharmacol 1991;32:483-8.
23. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
24. Sabatini U, Rascol O, Rascol A, Montastruc JL. Migraine attacks induced by subcutaneous apomorphine in 2 migrainous parkinsonian patients. Clin Neuropharmacol 1990;13:264-7.